|1.||Dal Pozzo, Fabiana: 1 article (04/2010)|
|2.||Vaccari, Francesca: 1 article (04/2010)|
|3.||Battilani, Mara: 1 article (04/2010)|
|4.||Galligioni, Viola: 1 article (04/2010)|
|5.||Gallina, Laura: 1 article (04/2010)|
|6.||Scagliarini, Alessandra: 1 article (04/2010)|
|7.||Matsuda, A: 1 article (05/2000)|
|8.||Gilbert, B E: 1 article (05/2000)|
|9.||Neyts, J: 1 article (05/2000)|
|10.||Moore-Poveda, D K: 1 article (05/2000)|
|1.||Body Weight (Weight, Body)
05/01/2000 - "However, both of these compounds were less effective against MV. On the basis of the pulmonary virus titers on day 4 after virus inoculation, the minimal efficacious dose of EICAR against MV (120 mg/kg of body weight/day when delivered intraperitoneally twice daily) appeared to be three times lower against this virus than that of ribavirin delivered at a similar dose (i.e., 360 mg/kg/day). "
07/01/1999 - "EICAR is a potent cytostatic agent that inhibits various tumor cells in culture including human solid tumor cells in vitro and in vivo. "
02/01/1991 - "Among these, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (6b, EICAR) is the most potent inhibitor of growth of the various tumor cells in culture including human solid tumor cells. "
01/01/1998 - "The cytostatic agent 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) causes a rapid and marked inhibition of inosinate (IMP) dehydrogenase activity in intact tumor cells. "
08/15/1999 - "The CTP synthetase inhibitors cyclopentenylcytosine and 3-deazauridine, the thymidylate synthase inhibitor 5-fluoro-2'-deoxyuridine, the dihydrofolate reductase inhibitor methotrexate, the IMP dehydrogenase inhibitors tiazofurin, ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) and mycophenolic acid, the ribonucleotide reductase inhibitors hydroxyurea and deferoxamine, and the DNA polymerase inhibitors ara-C, 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and aphidicolin, as well as several nucleoside analogs perturbing the DNA methylation pattern, have been found to induce tumor cell differentiation through impairment of DNA synthesis and/or function. "
04/01/2010 - "RBV and EICAR had a time- and concentration-dependent anti-CDV activity, mainly displayed during the first 10h post-infection. "
04/01/1991 - "EICAR is a candidate antiviral drug for the treatment of pox-, toga-, arena-, reo-, orthomyxo, and paramyxovirus infections."
03/01/1996 - "EICAR and pyrazofurin seem to be good candidates for further evaluation in an in vivo model of IPNV infection."
02/01/1992 - "EICAR and TJ13025 should be further pursued as candidate drugs for the treatment of ortho- and paramyxovirus infections."
|4.||Paramyxoviridae Infections (Parainfluenza)
|5.||Subacute Sclerosing Panencephalitis (SSPE)
04/01/1991 - "Similar in spectrum to ribavirin, EICAR was particularly active (50% inhibitory concentration, 0.2 to 4 micrograms/ml) against poxviruses (vaccinia virus), togaviruses (Sindbis and Semliki forest viruses), arenaviruses (Junin and Tacaribe viruses), reoviruses (reovirus type 1), orthomyxoviruses (influenza A and B viruses), and paramyxoviruses (parainfluenza virus type 3, measles virus, subacute sclerosing panencephalitis virus, and respiratory syncytial virus). "
|4.||3-Deazauridine (3 Deazauridine)
|6.||Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
|7.||Ribonucleotide Reductases (Ribonucleotide Reductase)